Stromelysin-1 (MMP-3) is a target and a regulator of Wnt1-induced epithelial-mesenchymal transition (EMT)

被引:50
作者
Blavier, Laurence [1 ,4 ]
Lazaryev, Alisa [1 ,4 ]
Shi, Xiang-He [1 ,4 ]
Dorey, Frederick J. [1 ,4 ]
Shackleford, Gregory M. [1 ,2 ,4 ]
DeClerck, Yves A. [1 ,3 ,4 ]
机构
[1] USC Keck Sch Med, Div Hematol Oncol, Dept Pediat, Los Angeles, CA 90089 USA
[2] USC Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA USA
[3] USC Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA USA
[4] Childrens Hosp Los Angeles, Saban Res Inst, Los Angeles, CA 90027 USA
基金
美国国家卫生研究院;
关键词
Wnt1; epithelial mesenchymal transition; MMPs; WNT SIGNALING PATHWAY; MATRIX METALLOPROTEINASES; BETA-CATENIN; BREAST-CANCER; MAMMARY-GLAND; TRANSGENIC MICE; CELLS; EXPRESSION; INHIBITOR; MATRILYSIN;
D O I
10.4161/cbt.10.2.12193
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Matrix metalloproteinases (MMPs) play a well-defined role in later stages of tumor progression. However, there has been evidence that they also contribute to earlier stages of malignant transformation. The Wnt signaling transduction pathway plays a critical role in development and in the pathogenesis of many epithelial cancers. Here we have used Wnt1-induced epithelial-mesenchymal transition (EMT) in C57MG murine mammary epithelial cells to study the role of MMPs in this early step of malignant progression. Overexpression of Wnt1 in C57MG cells promoted EMT, the translocation of beta-catenin from the cell membrane to the nucleus and its transcriptional activity, cell proliferation and cell motility. Simultaneously, we observed an increased expression of stromelysin-1 (MMP-3) and a 5.5-fold increase in MMP-3 promoter activity in C57MG cells expressing Wnt1 compared with C57MG cells. Treatment of Wnt-overexpressing cells with MMP inhibitor AG3340 decreased MMP-3 expression. We also found evidence that MMP-3 and Wnt3a cooperate in enhancing the transcriptional activity of beta-catenin in C57MG cells. Consistently, the effects of Wnt1 on EMT, proliferation and migration were inhibited by MMP inhibitors, or upon downregulation of MMP-3 by siRNA. These results suggest that MMP-3 is both a direct transcriptional target and a necessary contributor of the Wnt/beta-catenin signaling pathway.
引用
收藏
页码:198 / 208
页数:11
相关论文
共 50 条
[1]   Epithelial mesenchymal interactions in cancer and development [J].
Arias, AM .
CELL, 2001, 105 (04) :425-431
[2]   Functional interaction of beta-catenin with the transcription factor LEF-1 [J].
Behrens, J ;
vonKries, JP ;
Kuhl, M ;
Bruhn, L ;
Wedlich, D ;
Grosschedl, R ;
Birchmeier, W .
NATURE, 1996, 382 (6592) :638-642
[3]   Matrix metalloproteinases play an active role in Wnt1-induced mammary tumorigenesis [J].
Blavier, L ;
Lazaryev, A ;
Dorey, F ;
Shackleford, GM ;
DeClerck, YA .
CANCER RESEARCH, 2006, 66 (05) :2691-2699
[4]   CDNA CLONING AND EXPRESSION OF A METALLOPROTEINASE INHIBITOR RELATED TO TISSUE INHIBITOR OF METALLOPROTEINASES [J].
BOONE, TC ;
JOHNSON, MJ ;
DECLERCK, YA ;
LANGLEY, KE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (07) :2800-2804
[5]   Pharmacoproteomics of a metalloproteinase hydroxamate inhibitor in breast cancer cells: Dynamics of membrane type 1 matrix metalloproteinase-mediated membrane protein shedding [J].
Butler, Georgina S. ;
Dean, Richard A. ;
Tam, Eric M. ;
Overall, Christopher M. .
MOLECULAR AND CELLULAR BIOLOGY, 2008, 28 (15) :4896-4914
[6]   Wnt signaling: a common theme in animal development [J].
Cadigan, KM ;
Nusse, R .
GENES & DEVELOPMENT, 1997, 11 (24) :3286-3305
[7]   A high-affinity carbohydrate-containing inhibitor of matrix metalloproteinases [J].
Calderone, Vito ;
Fragai, Marco ;
Luchinat, Claudio ;
Nativi, Cristina ;
Richichi, Barbara ;
Roelens, Stefano .
CHEMMEDCHEM, 2006, 1 (06) :598-+
[8]   Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment [J].
Chantrain, CF ;
Shimada, H ;
Jodele, S ;
Groshen, S ;
Ye, W ;
Shalinsky, DR ;
Werb, Z ;
Coussens, LM ;
DeClerck, YA .
CANCER RESEARCH, 2004, 64 (05) :1675-1686
[9]  
CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620
[10]   Cancer therapy - Matrix metalloproteinase inhibitors and cancer: Trials and tribulations [J].
Coussens, LM ;
Fingleton, B ;
Matrisian, LM .
SCIENCE, 2002, 295 (5564) :2387-2392